The destruction of uranium enrichment sites that support Iran's nuclear program would not likely have severe environmental ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.

Dai-ichi Life Group has partnered with Capgemini to establish its first global capability center (GCC) outside Japan in Hyderabad, aiming to accelerate its digital transformation. This strategic ...

Fitch Ratings estimates that the deal is likely to increase Dai-ichi Life’s consolidated adjusted profit by approximately JPY15b per annum, or more or less $104.9m. Fitch anticipates minimal and ...

The latest international Daiichi Sankyo Co Ltd news and views from Reuters - one of the world's largest news agencies Skip to main content Exclusive news, data and analytics for financial market ...

Linklaters and Freshfields are advising on Dai-ichi Life Holdings' $1.1B acquisition in British money manager M&G. Advised by Linklaters, Dai-ichi Life Holdings—Japan’s largest publicly listed ...

The Minneapolis indie band 12 Rods, famous recipient of the first perfect 10 review in Pitchfork history during their initial 1992–2004 run, have been an on-off proposition since then. They ...

Dai-ichi Life Group was founded in 1902 as Japan’s first mutual life insurance company. It now serves over 50 million customers while managing approximately $430 billion in consolidated assets.

On June 1, Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: TROPION-Lung02, TROPION-Lung04, and NeoCOAST-2.

Hyderabad: Japanese life insurance player Dai-ichi Life Group signed a multi-year agreement with French IT services major Capgemini to set up its firs.

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get ...

Daiichi Sankyo signs a $300m deal with Alteogen to develop a subcutaneous version of anti-HER2 cancer drug Enhertu. Skip to main content Monday 30 June 2025 . BlueSky linkedin youtube rss ...